The unique circumstances that brought the H. Lee Moffitt Cancer Center and Research Institute to fruition only a decade ago continue to fuel its success today. Recently recognized by the National Cancer Institute as an NCI-designated center (P30CA76292), Moffitt was created by the Florida Legislature in the early 1980s to meet a compelling need to respond to a virtual epidemic of cancer in the state. The state mandate that the Center become a statewide research institute and a national resource for basic research, clinical research and multi-disciplinary approaches to patient treatment has provided the underpinning for a decade of phenomenal growth and rapid maturation. The center's mission remains totally focused on the prevention and cure of cancer. Moffitt's membership in the Eastern Cooperative Oncology Group begin in 1992, when John C. Ruckdeschel, M.D., arrived Albany Medical College as Center Director. The ECOG PI at Albany, Dr. Ruckdeschel immediately involved Moffitt in ECOG as an affiliate of Albany. The Center was subsequently funded through the ECOG Operations Office from 1992 to 1997, at which time ECOG institutional funding was awarded directly from the NCI (U10 CA73590) for the remaining two years of the grant cycle ending 4/3/99, with Henry Wagner, Jr., M.D., as Principal Investigator. The Moffitt Cancer Center's Consortia Membership took effect in 1993, and includes the James A. Haley Veterans Administration Hospital, located on the campus of the University of South Florida, and the Tampa General Hospital, located in downtown Tampa. The Moffitt Cancer Center offers ECOG several strong attributes: a large patient base, investigators experienced in cooperative group studies, in increasing emphasis on translational research and early phase trials with the expectation that promising studies will be passed to the cooperative groups for large scale testing. The institution is a consistently high accruer to ECOG trials, its investigators serve numerous administrative and scientific leadership positions, and the Center's Bone Marrow Transplant Program, the largest in the Southeast, was approved as an ECOG center for bone marrow transplantation in 1996. A cohort of Moffitt investigators, along with the extensive Cancer Control Research Program and Lifetime Cancer Screening Center, offers ECOG scientific leadership, laboratory support and potential patient accrual to cancer prevention studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA073590-07
Application #
6633223
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1997-06-16
Project End
2004-04-30
Budget Start
2003-05-01
Budget End
2004-04-30
Support Year
7
Fiscal Year
2003
Total Cost
$143,475
Indirect Cost
Name
University of South Florida
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
069687242
City
Tampa
State
FL
Country
United States
Zip Code
33612
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Walter, R B; Othus, M; Paietta, E M et al. (2015) Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 29:2104-7
Loughran Jr, T P; Zickl, L; Olson, T L et al. (2015) Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29:886-94
Ostronoff, Fabiana; Othus, Megan; Lazenby, Michelle et al. (2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol 33:1157-64

Showing the most recent 10 out of 45 publications